Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.86 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.86 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.86 |
| ▸ | DRD1 | P21728 | 3/20 | 0.86 |
| ▸ | DRD3 | P35462 | 3/20 | 0.86 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.86 |
| ▸ | HTR1A | P08908 | 2/20 | 0.86 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.86 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.86 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.86 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.86 |
| ▸ | BCL2 | P10415 | 1/20 | 0.86 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.83 |
| ▸ | TSHR | P16473 | 3/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorcyclizine SCHEMBL16769331 | 0.93 | KCNH2 (1.00) | CHRM2ADRA2ACHRM1DRD1DRD3 | |
| Chlorcyclizine SCHEMBL4383 | 0.93 | KCNH2 (1.00) | CHRM2ADRA2ACHRM1DRD1DRD3 | |
| Chlorcyclizine SCHEMBL12157065 | 0.93 | KCNH2 (1.00) | CHRM2ADRA2ACHRM1DRD1DRD3 | |
| Chlorcyclizine SCHEMBL13724147 | 0.93 | KCNH2 (1.00) | CHRM2ADRA2ACHRM1DRD1DRD3 | |
| Chlorcyclizine SCHEMBL321657 | 0.91 | CYP2D6 (1.00) | CHRM2ADRA2ACHRM1DRD1DRD3 | |
| Homochlorcyclizine SCHEMBL30402 | 0.87 | DRD3 (1.00) | CHRM2ADRA2ACHRM1DRD1DRD3 | |
| Homochlorcyclizine SCHEMBL1977999 | 0.86 | SMN1; SMN2 (1.00) | CHRM2ADRA2ACHRM1DRD1DRD3 | |
| Homochlorcyclizine SCHEMBL122573 | 0.86 | SMN1; SMN2 (1.00) | CHRM2ADRA2ACHRM1DRD1DRD3 | |
| SCHEMBL10677115 | 0.86 | CHRM2 (0.70) | CHRM2ADRA2ACHRM1DRD1DRD3 | |
| SCHEMBL25068897 | 0.84 | CHRM2 (0.64) | CHRM2ADRA2ACHRM1DRD1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS LTD. (GB) | 2023-02-23 | — | — | US | disclosed |
| WO-2022119362-A1 | GPX4 PROTEIN DEGRADATION-INDUCING COMPOUND | (주) 업테라 | 2022-06-09 | — | — | WO | disclosed |
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | disclosed |
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | disclosed |
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | disclosed |
| EP-3074001-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015080949-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015080949-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-06-04 | — | — | WO | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-6221868-B1 | Remedies/preventives for frequent urination/urinary incontinence and tropone derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-04-24 | — | — | US | disclosed |
| EP-0995741-A1 | REMEDIES/PREVENTIVES FOR FREQUENT URINATION/URINARY INCONTINENCE AND TROPONE DERIVATIVES | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | NCOR1, RRP15, NCOA1 | CHRM2 1157/4885ADRA2A 1044/4885CHRM1 420/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | CHRM2 776/4885ADRA2A 583/4885CHRM1 575/4885 |
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | FURIN, PFAS, CFTR | CHRM2 3400/4885ADRA2A 3550/4885CHRM1 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.